RxDoctor Payments Data

Galo Constante, MD

Internal Medicine · Fort Myers, FLNPI 1790768463

Payments from drug & device makers

$4,692in general payments, 2019–2025

Across 244 payments — averaging $19.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • GSK$661
  • Boehringer Ingelheim$654
  • Lilly USA, LLC$551
  • Amgen$305
  • Merck$290
  • plus $999 from 13 others

What the payments were for

  • Food & beverage$4,692100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,692 in reported general payments places this provider in the 85th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$109,937
Medicare patients
147
Services billed
1,668

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide50$84,372
EliquisApixaban44$53,138
Trelegy ElliptaFluticasone/Umeclidin/Vilanter37$51,506
JardianceEmpagliflozin26$34,431
XareltoRivaroxaban14$19,124
Repatha SureclickEvolocumab25$17,008
MounjaroTirzepatide14$14,374
ShingrixVaricella-Zoster Ge/As01b/Pf51$11,431
Novolin 70-30 FlexpenInsulin Nph Hum/Reg Insulin Hm17$2,956
Boostrix TdapDiphth,pertuss(Acell),tet Vac31$2,175
Memantine Hcl29$2,170
SynthroidLevothyroxine Sodium24$2,092
Rosuvastatin Calcium243$2,001
Lantus SolostarInsulin Glargine,hum.Rec.Anlog14$1,138
Amlodipine Besylate-BenazeprilAmlodipine Besylate/Benazepril66$963

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,231$84,37250 claims
GSKTrelegy Ellipta, Shingrix$661$62,93788 claims
PfizerEliquis$132$53,13844 claims
Boehringer IngelheimJardiance$654$34,43126 claims
Lilly USA, LLCMounjaro$551$14,37414 claims
AbbVieSynthroid$23$2,09224 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Fort Myers

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →